DULLES, Va., Feb. 11, 2026 — SOFIE Biosciences announced that the first patient has been dosed in its Phase 3 FAPI-PRO clinical trial evaluating [18F]FAPI-74, a fluorine-18–labeled radiopharmaceutical imaging agent, as a next-generation diagnostic tool for Pancreatic Ductal Adenocarcinoma (PDAC), marking a major advancement in precision oncology imaging and metastatic disease detection.
Science Significance
The Phase 3 initiation underscores growing scientific momentum behind fibroblast activation protein (FAP)–targeted imaging in oncology. [18F]FAPI-74 is a PET radiotracer designed to bind FAP-expressing cancer-associated fibroblasts, which are abundant in the tumor microenvironment of pancreatic and other solid malignancies. Unlike traditional glucose-based PET imaging, FAPI tracers visualize stromal biology rather than tumor metabolism, potentially improving lesion detection in fibrotic tumors such as PDAC. Prior Phase 2 and investigator-initiated studies demonstrated strong tumor avidity, favorable biodistribution, and high imaging contrast. The FAPI-PRO study will evaluate diagnostic performance in identifying metastatic disease, focusing on sensitivity and specificity for distant lesion detection—key determinants in treatment planning and surgical eligibility.
Regulatory Significance
Advancing into Phase 3 positions [18F]FAPI-74 within late-stage clinical validation required for regulatory approval as a diagnostic radiopharmaceutical. Imaging agents must demonstrate not only safety but also clinical utility in altering patient management decisions. The open-label, multi-site study design—planned across 18 centers with approximately 200 subjects—supports robust evidence generation for regulatory review. Parallel development of the FAPI-GO Phase 3 trial in gastroesophageal cancers strengthens the compound’s cross-tumor diagnostic value. Successful trial outcomes could support submissions to health authorities seeking approval for FAPI-based PET imaging in oncology staging workflows.
Business Significance
Advertisement
For SOFIE Biosciences, the trial reflects strategic expansion within the high-growth radiopharmaceutical and theranostics market. With established manufacturing and distribution infrastructure, the company is positioned to scale production of fluorine-18 tracers for clinical deployment. Proprietary FAPI intellectual property and clinical partnerships enhance competitive positioning as demand rises for tumor-microenvironment imaging. Advancing two Phase 3 programs simultaneously broadens commercial opportunity across multiple gastrointestinal malignancies while strengthening licensing, supply chain, and hospital network collaborations tied to molecular imaging adoption.
Patients’ Significance
For pancreatic cancer patients, improved imaging could significantly influence survival outcomes. PDAC is frequently diagnosed at advanced stages due to limited early detection and suboptimal imaging sensitivity. Accurate staging is critical in determining eligibility for surgery, systemic therapy, or clinical trials. FAPI-74 PET/CT imaging may enable earlier detection of metastatic disease, reducing unnecessary surgical interventions and guiding personalized treatment planning. Enhanced visualization of tumor spread could also support monitoring of therapeutic response and disease progression in high-risk populations.
Policy Significance
The trial reflects broader healthcare policy emphasis on precision diagnostics and theranostic integration in oncology care pathways. Regulators and payers are increasingly evaluating imaging technologies based on demonstrated impact on clinical decision-making and cost efficiency. FAP-targeted imaging also aligns with policy initiatives promoting biomarker-driven care, where diagnostic agents guide therapeutic selection. As radiopharmaceutical infrastructure expands globally, standardized production, distribution, and reimbursement frameworks will play a central role in ensuring equitable access to advanced molecular imaging.
With first patient dosing completed, the FAPI-PRO Phase 3 study advances [18F]FAPI-74 toward potential regulatory approval as a novel diagnostic imaging agent in pancreatic cancer. By targeting tumor-associated fibroblasts rather than cancer cells alone, the radiotracer represents a new frontier in oncologic visualization—bridging molecular biology, imaging science, and precision treatment planning in one of the deadliest solid tumors.
Source: SOFIE Biosciences press release
